Cytosorbents (CTSO) Competitors

$0.48 +0.00 (+0.21%)

As of 12:06 PM Eastern

CTSO vs. TMCI, CVRX, MBOT, SNWV, and RCEL

Should you buy Cytosorbents stock or one of its competitors? MarketBeat compares Cytosorbents with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytosorbents include Treace Medical Concepts (TMCI), CVRx (CVRX), Microbot Medical (MBOT), Sanuwave Health (SNWV), and Avita Medical (RCEL). These companies are all part of the "medical equipment" industry.

How does Cytosorbents compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Cytosorbents has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	0.89	-$59M	-$0.97	N/A
Cytosorbents	$37.20M	0.81	-$8.20M	-$0.19	N/A

Treace Medical Concepts presently has a consensus price target of $4.77, suggesting a potential upside of 63.13%. Cytosorbents has a consensus price target of $5.38, suggesting a potential upside of 1,019.79%. Given Cytosorbents' stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cytosorbents had 12 more articles in the media than Treace Medical Concepts. MarketBeat recorded 17 mentions for Cytosorbents and 5 mentions for Treace Medical Concepts. Treace Medical Concepts' average media sentiment score of 1.31 beat Cytosorbents' score of 0.34 indicating that Treace Medical Concepts is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Treace Medical Concepts	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Treace Medical Concepts has a net margin of -29.44% compared to Cytosorbents' net margin of -31.85%. Treace Medical Concepts' return on equity of -67.04% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-29.44%	-67.04%	-30.28%
Cytosorbents	-31.85%	-235.57%	-37.88%

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by insiders. Comparatively, 7.3% of Cytosorbents shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Treace Medical Concepts has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Summary

Treace Medical Concepts beats Cytosorbents on 8 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to CVRx?

CVRx (NASDAQ:CVRX) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

CVRx has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

75.3% of CVRx shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 13.9% of CVRx shares are owned by company insiders. Comparatively, 7.3% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cytosorbents had 12 more articles in the media than CVRx. MarketBeat recorded 17 mentions for Cytosorbents and 5 mentions for CVRx. CVRx's average media sentiment score of 0.54 beat Cytosorbents' score of 0.34 indicating that CVRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytosorbents has a net margin of -31.85% compared to CVRx's net margin of -89.14%. CVRx's return on equity of -120.76% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
Cytosorbents	-31.85%	-235.57%	-37.88%

Cytosorbents has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$59.07M	2.70	-$53.31M	-$2.02	N/A
Cytosorbents	$37.20M	0.81	-$8.20M	-$0.19	N/A

CVRx currently has a consensus target price of $11.50, suggesting a potential upside of 91.67%. Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,019.79%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than CVRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CVRx and Cytosorbents tied by winning 8 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

Microbot Medical currently has a consensus target price of $7.50, suggesting a potential upside of 339.88%. Cytosorbents has a consensus target price of $5.38, suggesting a potential upside of 1,019.79%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Microbot Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Microbot Medical has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

In the previous week, Cytosorbents had 7 more articles in the media than Microbot Medical. MarketBeat recorded 17 mentions for Cytosorbents and 10 mentions for Microbot Medical. Microbot Medical's average media sentiment score of 0.74 beat Cytosorbents' score of 0.34 indicating that Microbot Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Microbot Medical	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by insiders. Comparatively, 7.3% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cytosorbents has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	$105K	1,090.63	-$13.14M	-$0.26	N/A
Cytosorbents	$37.20M	0.81	-$8.20M	-$0.19	N/A

Microbot Medical has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Microbot Medical's return on equity of -21.84% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
Cytosorbents	-31.85%	-235.57%	-37.88%

Summary

Cytosorbents beats Microbot Medical on 9 of the 17 factors compared between the two stocks.

How does Cytosorbents compare to Sanuwave Health?

Sanuwave Health (NASDAQ:SNWV) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Sanuwave Health has a net margin of 35.96% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Sanuwave Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	35.96%	-450.56%	44.87%
Cytosorbents	-31.85%	-235.57%	-37.88%

Sanuwave Health has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Sanuwave Health has higher revenue and earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.34M	3.39	$11.81M	$0.33	52.91
Cytosorbents	$37.20M	0.81	-$8.20M	-$0.19	N/A

Sanuwave Health currently has a consensus target price of $51.00, indicating a potential upside of 192.10%. Cytosorbents has a consensus target price of $5.38, indicating a potential upside of 1,019.79%. Given Cytosorbents' higher possible upside, analysts clearly believe Cytosorbents is more favorable than Sanuwave Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

42.5% of Sanuwave Health shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by company insiders. Comparatively, 7.3% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cytosorbents had 8 more articles in the media than Sanuwave Health. MarketBeat recorded 17 mentions for Cytosorbents and 9 mentions for Sanuwave Health. Cytosorbents' average media sentiment score of 0.34 beat Sanuwave Health's score of -0.17 indicating that Cytosorbents is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanuwave Health	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytosorbents	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sanuwave Health beats Cytosorbents on 11 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to Avita Medical?

Cytosorbents (NASDAQ:CTSO) and Avita Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Cytosorbents currently has a consensus target price of $5.38, suggesting a potential upside of 1,019.79%. Avita Medical has a consensus target price of $7.25, suggesting a potential upside of 70.19%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Avita Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Avita Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cytosorbents had 6 more articles in the media than Avita Medical. MarketBeat recorded 17 mentions for Cytosorbents and 11 mentions for Avita Medical. Cytosorbents' average media sentiment score of 0.34 beat Avita Medical's score of 0.32 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytosorbents	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avita Medical	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytosorbents has a net margin of -31.85% compared to Avita Medical's net margin of -62.67%. Avita Medical's return on equity of 0.00% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Avita Medical	-62.67%	N/A	-76.31%

Cytosorbents has higher earnings, but lower revenue than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.20M	0.81	-$8.20M	-$0.19	N/A
Avita Medical	$71.61M	1.83	-$48.59M	-$1.57	N/A

Cytosorbents has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Avita Medical has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 27.7% of Avita Medical shares are owned by institutional investors. 7.3% of Cytosorbents shares are owned by company insiders. Comparatively, 2.8% of Avita Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Cytosorbents beats Avita Medical on 10 of the 16 factors compared between the two stocks.

Get Cytosorbents News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTSO vs. The Competition

Export

Metric	Cytosorbents	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.08M	$8.32B	$6.29B	$12.07B
Dividend Yield	N/A	2.53%	2.80%	5.32%
P/E Ratio	-2.52	16.05	20.62	25.05
Price / Sales	0.81	6.03	545.58	77.63
Price / Cash	N/A	16.74	27.48	37.30
Price / Book	5.33	3.64	9.73	6.60
Net Income	-$8.20M	$224.05M	$3.55B	$335.50M
7 Day Performance	-18.07%	-2.41%	-1.86%	-1.91%
1 Month Performance	-27.27%	-3.60%	-3.69%	-1.84%
1 Year Performance	-43.54%	0.74%	29.52%	27.02%

Cytosorbents Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTSO Cytosorbents	2.0887 of 5 stars	$0.48 +0.2%	$5.38 +1,019.8%	-46.8%	$30.08M	$37.20M	N/A	220	News Coverage Earnings Report Analyst Revision
TMCI Treace Medical Concepts	3.3724 of 5 stars	$2.29 +17.8%	$4.77 +108.8%	-59.1%	$148.03M	$207.32M	N/A	250	Positive News
CVRX CVRx	3.2288 of 5 stars	$5.40 -21.9%	$11.50 +112.8%	-6.3%	$142.83M	$56.65M	N/A	160	Analyst Upgrade Gap Down
MBOT Microbot Medical	2.3897 of 5 stars	$2.13 -3.0%	$7.50 +252.9%	-33.6%	$142.72M	N/A	N/A	20	Earnings Report Analyst Upgrade Gap Down
SNWV Sanuwave Health	1.8901 of 5 stars	$16.12 +0.7%	$51.00 +216.5%	-47.8%	$138.59M	$44.05M	N/A	40	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTSO) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytosorbents (CTSO) Competitors

CTSO vs. TMCI, CVRX, MBOT, SNWV, and RCEL

How does Cytosorbents compare to Treace Medical Concepts?

Summary

How does Cytosorbents compare to CVRx?

Summary

How does Cytosorbents compare to Microbot Medical?

Summary

How does Cytosorbents compare to Sanuwave Health?

Summary

How does Cytosorbents compare to Avita Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytosorbents (CTSO) Competitors

CTSO vs. TMCI, CVRX, MBOT, SNWV, and RCEL

How does Cytosorbents compare to Treace Medical Concepts?

Which has stronger valuation & earnings, TMCI or CTSO?

Do analysts recommend TMCI or CTSO?

Does the media refer more to TMCI or CTSO?

Is TMCI or CTSO more profitable?

Do institutionals & insiders hold more shares of TMCI or CTSO?

Which has more risk and volatility, TMCI or CTSO?

Summary

How does Cytosorbents compare to CVRx?

Which has more volatility & risk, CVRX or CTSO?

Do insiders and institutionals hold more shares of CVRX or CTSO?

Does the media favor CVRX or CTSO?

Is CVRX or CTSO more profitable?

Which has better valuation and earnings, CVRX or CTSO?

Do analysts recommend CVRX or CTSO?

Summary

How does Cytosorbents compare to Microbot Medical?

Do analysts prefer MBOT or CTSO?

Which has more risk & volatility, MBOT or CTSO?

Does the media refer more to MBOT or CTSO?

Do institutionals and insiders hold more shares of MBOT or CTSO?

Which has preferable valuation & earnings, MBOT or CTSO?

Is MBOT or CTSO more profitable?

Summary

How does Cytosorbents compare to Sanuwave Health?

Is SNWV or CTSO more profitable?

Which has more risk & volatility, SNWV or CTSO?

Which has stronger earnings and valuation, SNWV or CTSO?

Do analysts rate SNWV or CTSO?

Do insiders & institutionals believe in SNWV or CTSO?

Does the media favor SNWV or CTSO?

Summary

How does Cytosorbents compare to Avita Medical?

Do analysts recommend CTSO or RCEL?

Does the media refer more to CTSO or RCEL?

Is CTSO or RCEL more profitable?

Which has better earnings and valuation, CTSO or RCEL?

Which has more risk and volatility, CTSO or RCEL?

Do institutionals & insiders hold more shares of CTSO or RCEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools